[Advances in ulcer therapy].
D000535:Aluminum / Q000627:therapeutic use; D000863:Antacids / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use; D002229:Carbenoxolone / Q000627:therapeutic use; D003102:Colloids / Q000627:therapeutic use; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D010276:Parasympatholytics / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy*; D011619:Psychotropic Drugs / Q000627:therapeutic use; D012633:Secretin / Q000627:therapeutic use; D013004:Somatostatin / Q000627:therapeutic use; D013392:Sucralfate
D000863:Antacids; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D003102:Colloids; D006635:Histamine H2 Antagonists; D010276:Parasympatholytics; D011619:Psychotropic Drugs; D012633:Secretin; D013004:Somatostatin; D013392:Sucralfate; D000535:Aluminum; C031000:benzimidazole; D002229:Carbenoxolone
Fortschritte in der Ulkustherapie.